Global Information
회사소개 | 문의 | 위시리스트

제약, 바이오테크놀러지 및 진단 분야의 코프로모션 및 코마케팅 제휴 계약과 합의

Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2014-2019

리서치사 Current Partnering, a division of Wildwood Ventures Limited
발행일 2019년 04월 상품 코드 239653
페이지 정보 영문 250 Pages
가격
US $ 2,995 ₩ 3,667,000 PDF by E-mail (Single User License)
US $ 4,495 ₩ 5,505,000 PDF by E-mail (Multi user license - 2 to 5 Users)
US $ 8,995 ₩ 11,016,000 PDF by E-mail (Multi User Site License - 6+ Users)
US $ 14,995 ₩ 18,364,000 PDF by E-mail (Global license)


제약, 바이오테크놀러지 및 진단 분야의 코프로모션 및 코마케팅 제휴 계약과 합의 Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2014-2019
발행일 : 2019년 04월 페이지 정보 : 영문 250 Pages

세계 주요 헬스케어 기업의 코프로모션(Co-promotion) 및 코마케팅(Co-marketing) 제휴에 대해 조사하고, 코프로모션 및 코마케팅 거래 동향, 합의 구조, 계약 서류, 계약액별 주요 거래 및 가장 활발한 중개업자 등의 분석을 전해드립니다.

개요

제1장 서론

제2장 코프로모션 및 코마케팅 거래 형성 동향

  • 서론
  • 코프로모션과 코마케팅 거래의 차이
  • 코프로모션 거래 동향
  • 코마케팅 거래 동향
  • 전용 거래와 멀티 컴포넌트 거래
  • 거래에 코프로모션 선택사항을 포함하는 이유
  • 코프로모션권 보급
  • 교섭의 협상 카드로서의 코프로모션권
  • 공동 판촉 작업을 위한 파트너와의 제휴
  • 멀티 컴포넌트 거래 일부로서 코프로모션의 향후

제3장 코프로모션 거래 구조 개요

  • 서론
  • 전용 vs.멀티 컴포넌트 코프로모션 거래
  • 전용 코프로모션 합의 구조
  • 폭넓은 얼라이언스 합의의 일부로서 코프로모션권
  • 포함된 코프로모션권이 서드파티의 관여를 가능하게 한다

제4장 코마케팅 거래 구조 개요

  • 서론
  • 코마케팅 합의 구조
  • 폭넓은 얼라이언스 합의의 일부로서 코마케팅권

제5장 주요 코프로모션 거래

  • 서론
  • 주요 코프로모션 거래 : 거래액별
  • 가장 활발한 코프로모션 중개 기업
  • 대형 제약 기업의 코프로모션 거래 활동
  • 대형 바이오테크놀러지 기업의 코프로모션 거래 활동

제6장 주요 코마케팅 거래

  • 서론
  • 주요 코마케팅 거래 : 거래액별
  • 가장 활발한 코마케팅 중개 기업
  • 대형 제약 기업의 코마케팅 거래 활동

제7장 대형 제약 기업의 코프로모션 및 코마케팅 거래

  • 서론
  • 코프로모션 및 코마케팅 거래 이용법
  • 기업의 코프로모션 및 코마케팅 합의 목록

제8장 코프로모션 합의 디렉토리

  • 서론
  • 기업 : A-Z
  • 치료 분야별

제9장 코마케팅 합의 디렉토리

  • 서론
  • 기업 : A-Z
  • 치료 분야별

부록

도표

KSM 12.05.22

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

The Global Co-promotion and Co-marketing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2014-2019 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies.

The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2019 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies.

This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report covers details of co-promotion and co-marketing agreements from 2014 to 2019.

For pharmaceutical and biotechnology professionals, the report supplies a detailed understanding and analysis of how and why companies enter co-promotion and co-marketing deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to co-promote/market the resultant product of the research collaboration. There are also numerous pure co-promotion/marketing deals whereby the products originator takes on a co-promotion/marketing partner in order to maximize a products presence in the marketplace.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all co-promotion and co-marketing deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of co-promotion and co-marketing dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in co-promotion and co-marketing as well as a discussion on the merits of each type of deal.

Chapters 3 and 4 provide an overview of the structure of co-promotion and co-marketing deals, respectively. Each chapter includes numerous case studies to enable understanding of both pure co-promotion/marketing deals and multicomponent deals where co-promotion/marketing forms a part.

Chapter 5 provides a review of the leading co-promotion and co-marketing deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 6 provides a review of the top 50 most active biopharma companies in co-promotion and co-marketing. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 7 provides a comprehensive and detailed review of co-promotion and co-marketing deals signed and announced since 2014 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous table and figures that illustrate the trends and activities in co-promotion and co-marketing deal making since 2014.

In addition, a comprehensive appendix is provided organized by co-promotion and co-marketing company A-Z, stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about co-promotion and co-marketing partnering in the research, development and commercialization of technologies and products.

Key benefits

Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2019 report provides the reader with the following key benefits:

  • In-depth understanding of co-promotion and co-marketing deal trends since 2014
  • Analysis of the structure of co-promotion and co-marketing agreements with numerous real life case studies
  • Comprehensive access to over 700 actual co-promotion and co-marketing deals entered into by the world's biopharma companies
  • Insight into the terms included in a co-promotion and co-marketing agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

  • Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2019 report is intended to provide the reader with an in-depth understanding of the co-promotion and co-marketing trends and structure of deals entered into by leading biopharma companies worldwide.

Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2019 includes:

  • Trends in co-promotion and co-marketing dealmaking in the biopharma industry since 2014
  • Analysis of co-promotion and co-marketing deal structure
  • Case studies of real-life co-promotion and co-marketing deals
  • Access to over 700 co-promotion and co-marketing deal records
  • Detailed access to actual co-promotion contract documents
  • The leading co-promotion and co-marketing deals by value since 2014
  • Most active co-promotion and co-marketing dealmakers since 2014
  • The leading co-promotion and co-marketing partnering resources

In Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2019, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Therapeutic area
  • Technology area
  • Each deal title links via Weblink to an online version of deal record as found in the Current Agreements deals and alliances database, providing easy access to each deal record on demand.

The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2019 report provides comprehensive access to records for over 700 co-promotion and co-marketing deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise co-promotion and co-marketing rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Co-promotion and Co-marketing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2014-2019 provides the reader with the following key benefits:

  • In-depth understanding of co-promotion and co-marketing deal trends since 2014
  • Analysis of the structure of co-promotion and co-marketing agreements with numerous real life case studies
  • Comprehensive access to over 700 co-promotion and co-marketing deals entered into by the world's biopharma companies, together with contract documents if available
  • Detailed access to actual co-promotion and co-marketing contracts entered into by the leading fifty big pharma and big biotech companies
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
  • Identify leading co-promotion and co-marketing deals by value since 2014
  • Identify the most active co-promotion and co-marketing dealmakers since 2014
  • Full listing of co-promotion and co-marketing deals by company A-Z, headline value, phase of development, deal type, therapy and technology focus

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in co-promotion and co-marketing dealmaking

  • 2.1. Introduction
  • 2.2. Difference between co-promotion and co-marketing deals
  • 2.3. Trends in co-promotion deals since 2014
    • 2.3.1. Co-promotion and co-marketing dealmaking by year, 2014 to 2019
    • 2.3.2. Co-promotion and co-marketing dealmaking by phase of development, 2014 to 2019
    • 2.3.3. Co-promotion and co-marketing dealmaking by industry sector, 2014 to 2019
    • 2.3.4. Co-promotion and co-marketing dealmaking by therapy area, 2014 to 2019
    • 2.3.5. Co-promotion and co-marketing dealmaking by technology type, 2014 to 2019
    • 2.3.6. Co-promotion and co-marketing dealmaking by most active company, 2014 to 2019
  • 2.4. When co-marketing can be useful
  • 2.5. When co-marketing is the only option
  • 2.6. Pure deals and multi-component deals
    • 2.6.1. Attributes of pure co-promotion deals
    • 2.6.2. Attributes of co-promotion in multi-component deals
  • 2.7. Reasons for including co-promotion options in a deal
  • 2.8. Uptake of co-promotion rights
  • 2.9. Co-promotion rights as bargaining chips
  • 2.10. Aligning partners to make the co-promote work
  • 2.11. The future of co-promotion as part of multicomponent deals

Chapter 3 - Overview of co-promotion deal structure

  • 3.1. Introduction
  • 3.2. Pure versus multi-component co-promotion deals
  • 3.3. Pure co-promotion agreement structure
    • 3.3.1. Example co-promotion agreements
    • 3.3.1.a. Case study 1: Allergan - MAP Pharmaceuticals
    • 3.3.1.b. Case study 2: Genzyme - Veracyte
  • 3.4. Co-promotion rights as part of a wider alliance agreement
    • 3.4.1. Example co-promotion option clauses
    • 3.4.1.a. Case study 3: Takeda Pharmaceutical- Orexigen Therapeutics
    • 3.4.1.b. Case study 4: Celgene - Acceleron Pharma
    • 3.4.2. Example co-promotion right clauses
    • 3.4.2.a. Case study 5: Takeda - Orexigen
    • 3.4.2.b. Case study 6: Abbvie - Receptos
  • 3.5. Embedded co-promotion rights enabling third party engagement
    • 3.5.1. Example co-promotion clauses enabling third party engagement
    • 3.5.1.a. Case study 7: Astellas - Ambit Biosciences

Chapter 4 - Overview of co-marketing deal structure

  • 4.1. Introduction
  • 4.2. Co-marketing agreement structure
    • 4.2.1. Example co-marketing agreements
    • 4.2.1.a. Case study 8: AstraZeneca -Ironwood Pharmaceuticals
  • 4.3. Co-marketing rights as part of a wider alliance agreement
    • 4.3.1. Example co-marketing right clauses
    • 4.3.1.a. Case study 9: Lundbeck - Myriad Genetics

Chapter 5 - Leading co-promotion and co-marketing deals

  • 5.1. Introduction
  • 5.2. Top co-promotion and co-marketing deals by value

Chapter 6 - Top 25 most active co-promotion and co-marketing dealmakers

  • 6.1. Introduction
  • 6.2. Top 25 most active co-promotion and co-marketing dealmakers

Chapter 7 - Co-promotion and co-marketing agreement contracts directory 2014- 2019

  • 7.1. Introduction
  • 7.2. Co-promotion and co-marketing deals with contracts 2014 to 2019

Appendices

  • Appendix 1 - Co-promotion and co-marketing deals by company A-Z
  • Appendix 2 - Co-promotion and co-marketing deals by stage of development
  • Appendix 3 - Co-promotion and co-marketing deals by deal type
  • Appendix 4 - Co-promotion and co-marketing deals by therapy area
  • Appendix 5 - Co-promotion and co-marketing deals by technology type
  • Appendix 6 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

TABLE OF FIGURES

  • Figure 1: Definition of co-promotion and co-marketing
  • Figure 2: Trends in co-promotion and co-marketing deal announcements, 2014 to 2019
  • Figure 3: Co-promotion and co-marketing deals signed at each phase of development, 2014 to 2019
  • Figure 4: Co-promotion and co-marketing deals by industry sector, 2014 to 2019
  • Figure 5: Co-promotion and co-marketing deals by therapy area, 2014 to 2019
  • Figure 6: Co-promotion and co-marketing deals by technology type, 2014 to 2019
  • Figure 7: Top 25 most active co-promotion and co-marketing dealmakers, 2014 to 2019
  • Figure 8: Situations where co-marketing can prove useful
  • Figure 9: Key components of a pure co-promotion deal
  • Figure 10: Key components of a multi-component co-promotion deal
  • Figure 11: Example deals where co-promotion options have been actively exercised, since 2000
  • Figure 12: Issues in implementing co-promotion agreements
  • Figure 13: Co-promotion agreements - what should a contract include?
  • Figure 14: Components of the co-promotion deal structure
  • Figure 15: Components of the co-marketing deal structure
  • Figure 16: Top co-promotion and co-marketing deals by value since 2014
  • Figure 17: Most active co-promotion and co-marketing dealmakers 2014 to 2019
Back to Top
전화 문의
F A Q